Carrier T-VISA for expressing target genes at high efficiency and high specificity in tumor cells

Abstract

The invention discloses a carrier for expressing target genes at high efficiency and high specificity in tumor cells, which is an annular carrier with the sequence shown as SEQ ID NO. 1. The carrier T-VISA can express the target genes at high efficiency and high specificity in the tumor cells, the expression effect is the same as that of a cytomegalovirus (CMV) promoter, and the carrier T-VISA has the characteristic that the expression in normal tissue cells is very low. Therefore, the carrier T-VISA provided by the invention has wide application values that: 1, the carrier T-VISA can be used for driving any target genes to express at high efficiency and high specificity in the tumor cells, including gene reporting such as luciferase and green fluorescent protein (GFP) and gene treatment genes such as p53 (cell apoptosis protein genes), IL-2 (immune regulation protein genes) and the like; and 2, the carrier T-VISA can be used for the study and the application of tumor biology, tumor signal conduction, tumor gene regulation and control and gene treatment after being combined with corresponding target genes.

Description

Technical field: [0001] The invention belongs to the field of biomedicine, and in particular relates to a carrier T-VISA for highly efficient and highly specific expression of target genes in tumor cells. Background technique: [0002] In tumor cells, high-efficiency and high-specific expression of target genes is an important method for studying tumor biology, tumor signal transduction, tumor gene regulation and gene therapy. The current tumor-specific promoters used to express target genes have low activity and poor efficiency, making it difficult to conduct in-depth studies on tumor biology, signal transduction and gene regulation, especially resulting in the inability of clinical application of tumor gene therapy. Gene therapy has a development history of more than 20 years, and people hope that it can become an effective alternative therapy besides surgical resection, radiotherapy and chemotherapy. At present, the cytomegalovirus promoter (CMV), which is mostly used in...

AI Technical Summary

Problems solved by technology

At present, the cytomegalovirus promoter (CMV), which is mostly used in tumor gene therapy, is currently the most active promoter, but the promoter has no specificity and highly expresses the target gene in normal cells. Although the developed clinical trial products have certain curative effect, but the side effects are large, and it cannot be approved by SFDA (China Food and Drug Administration) and U.S. FDA (Food and Drug Administration) for clinical use.

Some people use tumor-specific promoters, which greatly reduce the toxic and side effects, but due to low activity, its efficacy has become very limited

Images